USA flag logo/image

An Official Website of the United States Government

Human Proteome Arrays for Auto-Antibody Identification in Clinical Cancer…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88870
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA130391
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Meso Scale Diagnostics
1601 Research Boulevard Rockville, MD 20850-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Human Proteome Arrays for Auto-Antibody Identification in Clinical Cancer Studies
Agency: HHS
Contract: 1R44CA130391-01A1
Award Amount: $230,965.00
 

Abstract:

DESCRIPTION (provided by applicant): Human Proteome Arrays for Auto-Antibody Identification in Clinical Cancer Studies The goal of this project is to develop protein arrays on a proteome scale for high throughput discovery and validation of cancer-specific autoantibody signatures. Early detection of cancer is a critical factor for the successful treatment of cancer patients. The discovery of specific autoantibody signatures in cancer patients has led to the recognition that autoantibody responses may have d iagnostic potential. The lack of high throughput methods for rapidly screening and validating multiple antigens of interest has been identified as an important bottleneck for the development of autoantibodies as biomarkers for cancer diagnosis. We will tes t normal and cancer patient sera against protein arrays generated using a gene library expressing human full-length proteins. Autoantibodies against the proteins in these arrays will be identified using electrochemiluminescence (ECL) detection technology, a proven technology for high throughput array-based measurements that will enable studies with large numbers of patient samples. Our approach will offer key advantages over existing array-based approaches by providing a high throughput, sensitive and speci fic assay platform. This approach will also facilitate the rapid transition from discovery of antigens using large arrays to clinical validation of the hits using small focused arrays on the same diagnostic platform. In the Phase I portion of the proposed project, we will demonstrate technical feasibility of the approach; in the Phase II portion we will develop and validate the proteome-scale arrays, and use them to screen cancer serum samples to identify a promising subset of autoantigens; the selected sub set will then be further tested with a large number of individual samples.

Principal Investigator:

Business Contact:


cclinton@mesoscale.com
Small Business Information at Submission:

MESO SCALE DIAGNOSTICS, LLC
MESO SCALE DIAGNOSTICS, LLC 9238 GAITHER RD GAITHERSBURG, MD 20877

EIN/Tax ID: 521974952
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No